Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study at Tristan Manalac

Location: Unknown.

Employment type: full-time.

Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among others, in this space.